Primary Hyperoxaluria: The Patient and Caregiver Perspective.
作者信息
Lawrence Jennifer E, Wattenberg Debra J
机构信息
Oxalosis and Hyperoxaluria Foundation, New York, New York
Oxalosis and Hyperoxaluria Foundation, New York, New York.
出版信息
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):909-911. doi: 10.2215/CJN.13831119. Epub 2020 Mar 12.
Abstract
摘要
相似文献
1
Primary Hyperoxaluria: The Patient and Caregiver Perspective.
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):909-911. doi: 10.2215/CJN.13831119. Epub 2020 Mar 12.
2
Primary hyperoxaluria.
N Engl J Med. 2013 Aug 15;369(7):649-58. doi: 10.1056/NEJMra1301564.
3
Combined liver and kidney transplantation in primary hyperoxaluria type 1 in children.
Transplant Proc. 1994 Feb;26(1):110-1.
4
Atypical features of primary hyperoxaluria in end-stage renal disease.
Am J Nephrol. 1991;11(4):301-4. doi: 10.1159/000168326.
5
Primary hyperoxaluria: a rare but important cause of nephrolithiasis.
Hong Kong Med J. 2002 Jun;8(3):202-6.
6
End Points for Clinical Trials in Primary Hyperoxaluria.
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065. doi: 10.2215/CJN.13821119. Epub 2020 Mar 12.
7
[Primary hyperoxaluria in children in central Tunisia].
Tunis Med. 2007 Jun;85(6):513-8.
8
Hyperoxaluria and renal calculi in children: the role of extracorporeal shock wave lithotripsy.
J R Soc Med. 1988 Oct;81(10):604-5. doi: 10.1177/014107688808101019.
9
Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.
BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1.
10
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
Kidney Int. 2019 Dec;96(6):1389-1399. doi: 10.1016/j.kint.2019.08.018. Epub 2019 Sep 3.
引用本文的文献
1
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.
Front Pediatr. 2024 Sep 16;12:1392644. doi: 10.3389/fped.2024.1392644. eCollection 2024.
2
Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.
Kidney Dis (Basel). 2024 Jun 17;10(4):313-326. doi: 10.1159/000539516. eCollection 2024 Aug.
3
Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.
BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1.
4
Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?
J Nephrol. 2023 Jun;36(5):1473-1476. doi: 10.1007/s40620-023-01611-1. Epub 2023 May 20.
5
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis. 2023 Apr 28;51(1):80. doi: 10.1007/s00240-023-01453-3.
6
Healthcare utilization, quality of life, and work productivity associated with primary hyperoxaluria: a cross-sectional web-based US survey.
Urolithiasis. 2023 Apr 17;51(1):72. doi: 10.1007/s00240-023-01436-4.
7
Monogenic urinary lithiasis in Tunisian children: 25 years' experience of a referral center.
Tunis Med. 2022;100(5):410-415.
8
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
Pediatr Nephrol. 2023 Apr;38(4):1075-1086. doi: 10.1007/s00467-022-05684-1. Epub 2022 Aug 1.
9
End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease.
Am J Kidney Dis. 2022 May;79(5):754-756. doi: 10.1053/j.ajkd.2021.09.005. Epub 2021 Oct 8.
10
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study.
Front Med (Lausanne). 2021 Sep 20;8:703305. doi: 10.3389/fmed.2021.703305. eCollection 2021.
Zotero 插件